What's Going On With Moderna Stock Wednesday
Portfolio Pulse from Dylan Berman
Moderna, Inc. (NASDAQ:MRNA) received a $176 million award to boost its Influenza vaccine development. The company is working on an mRNA-based vaccine against the H5 influenza virus, with Phase 1/2 study results expected in 2024. Additionally, Moderna's RSV vaccine received a positive opinion from the Committee for Medicinal Products for Human Use, potentially leading to marketing authorization in the EU.
July 03, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna received a $176 million award to develop an mRNA-based Influenza vaccine and received positive regulatory feedback for its RSV vaccine in the EU.
The $176 million award will significantly boost Moderna's R&D capabilities for its Influenza vaccine, potentially leading to new revenue streams. The positive opinion for the RSV vaccine in the EU could lead to market authorization, further enhancing revenue prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100